Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue from contracts with customers (Details)

v3.24.2.u1
Revenue - Revenue from contracts with customers (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2024
USD ($)
contract
Jun. 30, 2023
USD ($)
contract
Jun. 30, 2024
USD ($)
contract
Jun. 30, 2023
USD ($)
contract
Dec. 31, 2023
USD ($)
Revenue          
Revenue $ 128,231,000 $ 5,130,000 $ 133,909,000 $ 52,731,000  
Number of contracts with customers | contract 3 3 3 2  
Deferred revenue decrease         $ 39,756,000
Deferred revenue $ 138,277,000   $ 138,277,000   $ 178,033,000
Amount of increase in deferred income caused by the change in the exchange rate     $ 1,211,000    
Exchange rate 1.26   1.26   1.27
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements $ 154,393,000   $ 154,393,000    
Revenue recognized in the period     133,011,000    
Development revenue          
Revenue          
Revenue $ 128,231,000 $ 5,130,000 133,909,000 $ 52,731,000  
Galapagos Collaboration and Exclusive License Agreement          
Revenue          
Milestone payments received     85,000,000    
GSK Collaboration And License Agreement          
Revenue          
Milestone payments received     $ 9,583,000